Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13690MR)

This product GTTS-WQ13690MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13690MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2525MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ7841MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ1322MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ5874MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ12704MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ9182MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ10367MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ12647MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-131R10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW